{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":300,"width":600,"title":"\ud83d\udee1\ufe0f One Risk Factor in Atrial Fibrillation: Is It Time for a DOAC?","description":"\ud83e\udec0 AF + just one stroke-risk factor: anticoagulate or not? The SINGLE-AF randomized trial tackled this common clinical gray zone. At 24 months, the composite of stroke, systemic embolism, major bleeding, or cardiovascular death occurred in 0.5% with a DOAC vs 1.5% without anticoagulation (HR 0.31; P=0.03). \ud83c\udfaf \u26a0\ufe0f Only 17 primary events occurred, so the effect estimate remains imprecise. Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk.pdf \ud83d\udca1 Takeaway: SINGLE-AF strengthens the case for DOAC therapy in selected intermediate-risk AF patients\u2014but individualized decision-making remains essential. ","author_name":"Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!","author_url":"http:\/\/www.MasterMedFacts.com","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/42597785\/height\/300\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"300\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/205565020"}